Payment overview · 2025
General Payments
$606.76
23 reported records · 9 companies
Healthcare provider profile · identity verified
Natalya Chalik, MD
Allopathic & Osteopathic Physicians|Internal Medicine · STATEN ISLAND, NY · NPI 1780745299
Verified facts
What the public records show
CMS Open Payments records show Natalya Chalik, MD received $606.76 in general payments during 2025 across 23 reported records.
AstraZeneca Pharmaceuticals LP accounted for 31.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $193.62 | 31.9% | 5 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $150.18 | 24.8% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $128.87 | 21.2% | 5 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $43.50 | 7.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $30.91 | 5.1% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $16.28 | 2.7% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $15.85 | 2.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.94 | 2.3% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.61 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $606.76 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $157.36 | 3 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $150.18 | 6 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $150.18 | 6 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $150.18 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $147.46 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $128.87 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $111.20 | 1 | 2025 |
Source payment records
|
|||||
| APLENZIN Normalized: aplenzin |
Drug | Bausch Health US, LLC | $43.50 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $30.91 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $30.91 | 1 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $16.28 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $15.85 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.94 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 135 | 45 |
| Amlodipine Besylate | Amlodipine Besylate | 123 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 120 | 39 |
| Levothyroxine Sodium | Levothyroxine Sodium | 115 | 30 |
| Losartan Potassium | Losartan Potassium | 112 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 91 | 29 |
| Oxycodone Hcl | Oxycodone Hcl | 85 | suppressed |
| Gabapentin | Gabapentin | 76 | 18 |
| Omeprazole | Omeprazole | 71 | 23 |
| Simvastatin | Simvastatin | 63 | 17 |
| Metformin Hcl Er | Metformin Hcl | 60 | 21 |
| Dexlansoprazole Dr | Dexlansoprazole | 58 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 55 | suppressed |
| Ozempic | Semaglutide | 51 | suppressed |
| Vascepa | Icosapent Ethyl | 50 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 46 | 11 |
| Famotidine | Famotidine | 45 | 13 |
| Allopurinol | Allopurinol | 43 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 43 | 15 |
| Furosemide | Furosemide | 40 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | suppressed |
| Synthroid | Levothyroxine Sodium | 38 | suppressed |
| Nifedipine Er | Nifedipine | 37 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 35 | suppressed |
| Lisinopril | Lisinopril | 34 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 33 | suppressed |
| Metformin Hcl | Metformin Hcl | 32 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 32 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 31 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 30 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 29 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | suppressed |
| Valsartan | Valsartan | 27 | 11 |
| Celecoxib | Celecoxib | 26 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 26 | suppressed |
| Silodosin | Silodosin | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 24 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 23 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 21 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Carvedilol | Carvedilol | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 17 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | 13 |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Cozaar | Losartan Potassium | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Jardiance | Empagliflozin | 13 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 12 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $606.76 · 23 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, APLENZIN, BREZTRI, Cologuard Collection Kit, FARXIGA, GLYCATE, JARDIANCE, NEFFY, NURTEC ODT, RELTONE 200 MG, RELTONE 400 MG, Xhance, ZAVZPRET, ZORYVE | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error